贵阳新天药业股份有限公司关于控股股东减持股份触及1%的公告

Core Viewpoint - The controlling shareholder of Guizhou Xintian Pharmaceutical Co., Ltd. plans to reduce its shareholding, which has triggered a notification due to the change in equity ratio reaching 1% [1][2]. Shareholder Reduction Details - The controlling shareholder, Shanghai Xintian Zhiyao Biotechnology Co., Ltd., holds 75,485,566 shares, accounting for 32.0809% of the total share capital after excluding shares in the repurchase account [2]. - The planned reduction includes a maximum of 7,050,000 shares, representing 2.9962% of the total share capital after excluding shares in the repurchase account. This consists of up to 4,700,000 shares through block trading (6.2264% of its total shares) and up to 2,350,000 shares through centralized bidding (3.1132% of its total shares) [2]. - As of November 12, 2025, the controlling shareholder has reduced its holdings by 800,000 shares, which is 0.3277% of the total share capital, bringing its total holdings to 74,685,566 shares and reducing its ownership percentage to 31.7409% [2]. Equity Change Notification - The reduction in shareholding has triggered a notification as the equity change has reached 1% [3].